Q3 Results impact: Havells India shares drop 7% as profit misses estimates; Aarti Surfactants, Tips Music jump up to 20%
Along with the Q3 results, Havells India announced an interim dividend of Rs 4 per equity share.
December flight chaos may cost IndiGo over Rs 2,000 crore
The estimated hit includes major cost items such as ticket refunds, regulator-mandated passenger compensation and goodwill gestures announced by the airline apart from other smaller but significant expenses
OPINION | What AI changes for mobile developers - and what it doesn't
AI changes the tools, cost structures and even what users expect. What it doesn't change: the hard work of figuring out what's worth building, for whom, and why they'll care. That's still the game
Sensex falls 3,800 pts in 7 weeks, Nifty down 4%: Should you stop your SIP for a while? Here's what market experts say
SIP allocations during lower market levels allows investors to accumulate more units at reduced prices, which incrementally improves long-term returns and compounding, an analyst explained.
Shadowfax leans on value-added services as it takes on a crowded logistics market
The company sees a strong growth pipeline from existing clients and new D2C additions, while aspiring for mid-teens EBITDA margins over the long term.
PhonePe gets SEBI nod for India's second largest fintech IPO, likely to seek $15-billion valuation
The stage is set for PhonePe’s listing in the Indian stock markets as the company continues to reign in UPI payments segment with around 45 percent market share
Gold ETFs surge up to 9% to fresh record highs as yellow metal’s Feb futures cross Rs 1.5 lakh/10 grams: What lies ahead?
The future contracts with April and June expiries meanwhile surged around 5% each to hit new all-time highs of Rs 1,58,200 per 10 grams and Rs 1,62,299 per 10 grams respectively.
Bank Nifty extends decline for 2nd day; PSU bank index falls 1.4%: What should investors do?
Axis Securities said that Bank Nifty is centered around the 60,000 level, which is acting as a key pivot for the current expiry
Real estate stocks see worst day in six months; Oberoi Realty falls 9% over weak Q3 results: What lies ahead?
The sharp fall in the share prices pushed the Nifty Realty index down more than 4% to emerge as the top sectoral loser today and recording decline for the third consecutive session.
Silver ETFs soar up to 10% to record highs as precious metal's March futures cross Rs 3.2 lakh/kg: Should you buy now?
For those looking at fresh investment, the main risk right now is valuation and sentiment, an analyst said.
Strong market debut: Avana Electrosystems shares list at 31% premium to SME IPO price, beat GMP estimates
Avana Electrosystems IPO GMP: Ahead of listing, the unlisted shares of the company were trading with 18-19% GMP over the IPO price.
OPINION | India’s alcobev imports face tariff reckoning in Budget 2026
As Budget 2026 nears, India’s alco-bev industry seeks tariff rationalization, customs amnesty, and procedural clarity to unlock growth, reduce litigation, and support premium imports amid expanding trade agreements
Shadowfax IPO subscribed 47% on Day 1, retail portion fully booked: Analysts highlight long-term potential despite GMP drop
Shadowfax Tech aims to raise Rs 1,907.2 crore through its IPO, which comprises a fresh issue of shares worth Rs 1,000 crore and an OFS of shares worth Rs 907.2 crore by several investors.
Hindustan Zinc shares jump 5% as soaring silver prices boost Q3 results: Should you buy, sell or hold?
Hindustan Zinc share price: HSBC expects Q4 results to be even stronger due to higher volumes and sharply higher silver prices.
UPL subsidiary Advanta Enterprises files IPO papers with SEBI
Advanta Enterprises IPO | The proposed IPO will be entirely an Offer-for-Sale (OFS) of 3.61 crore equity shares, with no fresh issue component.
Davos 2026: “Only a fool would overlook India,” says Cerebras CEO Andrew Feldman on AI partnerships
Feldman says India’s talent, infrastructure push and partnership ecosystem make it impossible for global AI companies to ignore the country.
India’s healthcare deals top Rs 10,000 crore in Q2FY26 as hospitals, diagnostics lead expansion: EY
Private equity and strategic investors continued to chase scalable regional platforms with strong clinical depth and technology‑enabled models, EY report said.
Shadowfax Technologies raises Rs 856 cr via anchor book ahead of IPO, ICICI Prudential AMC largest investor
Shadowfax Technologies IPO | ICICI Prudential AMC was the largest investor in the anchor book, acquiring 1.53 crore equity shares for Rs 190 crore through its four schemes.
Armour Security India IPO attracts 2 times subscription on final day, listing likely on January 22
Armour Security IPO | The New Delhi-headquartered company is raising Rs 26.5 crore via initial public offering (IPO) at the upper end of price band of Rs 55-57 per share.
LTIMindtree Q3 results: Net profit falls 12% to Rs 960 crore due to labour code charges
Total headcount as of December 31 was around 87,958 professionals. LTIMindtree added 1,511 employees in Q3.
Sun Pharma terms $10-billion Organon buy report as 'speculative'
A report on Monday said that Sun Pharma is evaluating a takeover of Organon & Co. in a transaction that could be valued at about $10 billion including debt, a move that would mark the biggest overseas acquisition ever by an Indian drugmaker.
Tata Capital Q3 results: Net profit rises 17% to Rs 1,257 crore
The Tata group firm's consolidated interest income increased 10% to Rs 7,242 crore in Q3FY26 as against Rs 6,585 crore in Q3FY25
Bajaj Auto readies smaller KTMs, Triumphs to qualify for lower GST slab
The GST rate on two-wheelers with engines up to 350cc was reduced by 10 percentage points to 18 percent, effective September 22, 2025
OPINION | Leadership as collective capability, not personal dominance
Effective institutional design reduces dependence on individuals by strengthening systems, shared leadership, and accountability, enabling organisations to learn from failure, sustain purpose, and remain resilient through leadership transitions
We can launch a new drug every 2 or 3 years, Wockhardt chairman Khorakiwala
The portfolio stays firmly anchored in antibiotics, an area big pharma abandoned due to low commercial returns, with focus on products that can fight mult-drug resistant infections
